Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients

被引:38
|
作者
Nuytemans, Karen [1 ,2 ,3 ]
Rademakers, Rosa [1 ,2 ,3 ]
Theuns, Jessie [1 ,2 ,3 ]
Pals, Philippe [2 ,3 ,4 ]
Engelborghs, Sebastiaan [3 ,5 ]
Pickut, Barbara [6 ]
de Pooter, Tim [1 ,2 ,3 ]
Peeters, Karin [1 ,2 ,3 ]
Mattheijssens, Maria [1 ,2 ,3 ]
Van den Broeck, Marleen [1 ,2 ,3 ]
Cras, Patrick [3 ,4 ]
De Deyn, Peter Paul [3 ,5 ,6 ]
van Broeckhoven, Christine [1 ,2 ,3 ]
机构
[1] Univ Antwer, Neurodegenerat Brain Dis Grp, Dept Mol Genet, CDE,VIB, B-2610 Antwerp, Belgium
[2] Inst Born Bunge, Neurogenet Lab, Antwerp, Belgium
[3] Univ Antwerp, Born Bunge Fdn, Neurobiol Lab, B-2020 Antwerp, Belgium
[4] Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium
[5] Inst Born Bunge, Lab Neurochem & Behav, Antwerp, Belgium
[6] ZNA Middleheim Gen Hosp, Div Neurol, Antwerp, Belgium
关键词
Parkinson's disease; LRRK2; p.R1441C founder mutation;
D O I
10.1038/sj.ejhg.5201986
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We determined the prevalence of mutations in two major functional domains of the leucine-rich repeat kinase 2 gene (LRRK2) in Belgian Parkinson's disease (PD) patients (N = 304) of which 18.1% were familial PD patients. Ten patients were heterozygous for five different missense mutations (3.29%) of whom six carried the same mutation p. R1441C (1.97%). All six p. R1441C carriers were familial PD patients explaining 10.7% of familial PD in the Belgian patient group. Moreover, they shared a common disease haplotype of 21 consecutive markers in a region of 438 kb, suggesting that they are distant descendants of a single common ancestor. Clinically, p. R1441C carriers had typical levodopa-responsive parkinsonism with tremor as the most common presenting feature. Their age at onset was highly variable and ranged from 39 to 73 years, suggesting the influence of modifying factors. The remaining four patients were heterozygous each for a novel missense mutation located in the Roc or kinase domain. The pathogenic nature of these mutations remains to be determined, though we have genetic evidence that at least some represent rare but benign variants rather than causal mutations. The latter observation indicates that prudence is needed in diagnostic testing of LRRK2 in PD patients. Functional data should underlie a conclusion on the pathogenic nature of some mutations that have not been conclusively linked to disease.
引用
收藏
页码:471 / 479
页数:9
相关论文
共 50 条
  • [21] Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson’s disease
    Julie P. Taylor
    Mary M. Hulihan
    Jennifer M. Kachergus
    Heather L. Melrose
    Sarah J. Lincoln
    Kelly M. Hinkle
    Jeremy T. Stone
    Owen A. Ross
    Robert Hauser
    Jan Aasly
    Thomas Gasser
    Haydeh Payami
    Zbigniew K. Wszolek
    Matthew J. Farrer
    Neurogenetics, 2007, 8 : 95 - 102
  • [22] Leucine-rich repeat kinase 1:: a paralog of LRRK2 and a candidate gene for Parkinson's disease
    Taylor, Julie P.
    Hulihan, Mary M.
    Kachergus, Jennifer M.
    Melrose, Heather L.
    Lincoln, Sarah J.
    Hinkle, Kelly M.
    Stone, Jeremy T.
    Ross, Owen A.
    Hauser, Robert
    Aasly, Jan
    Gasser, Thomas
    Payami, Haydeh
    Wszolek, Zbigniew K.
    Farrer, Matthew J.
    NEUROGENETICS, 2007, 8 (02) : 95 - 102
  • [23] A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation
    Ahamadi, Malidi
    Mehrotra, Nitin
    Hanan, Nathan
    Lai Yee, Ka
    Gheyas, Ferdous
    Anton, Judith
    Bani, Massimo
    Boroojerdi, Babak
    Smit, Hans
    Weidemann, Jonas
    Macha, Sreeraj
    Thuillier, Vincent
    Chen, Chao
    Yang, Minhua
    Williams-Gray, Caroline H.
    Stebbins, Glenn T.
    Pagano, Gennaro
    Hang, Yaming
    Marek, Kenneth
    Venuto, Charles S.
    Javidnia, Monica
    Dexter, David
    Pedata, Anne
    Stafford, Bob
    Akalu, Mussie
    Stephenson, Diane
    Romero, Klaus
    Sinha, Vikram
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (02) : 508 - 518
  • [24] A new approach to Parkinson's disease: inhibition of leucine-rich repeat kinase-2
    Doggrell, Sheila A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (04) : 587 - 590
  • [25] Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2
    Tong, Youren
    Shen, Jie
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 1042 - 1046
  • [26] Colonic Leucine-Rich Repeat Kinase 2 Expression Is Increased and Associated With Disease Severity in Patients With Parkinson's Disease
    Liao, Peng-Hsiang
    Chiang, Han-Lin
    Shun, Chia-Tung
    Hang, Jen-Fan
    Chiu, Han-Mo
    Wu, Ming-Shiang
    Lin, Chin-Hsien
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 13
  • [27] Dyskinesias in patients with Parkinson's disease: Effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation
    Yahalom, Gilad
    Kaplan, Natalie
    Vituri, Aya
    Cohen, Oren S.
    Inzelberg, Rivka
    Kozlova, Evgenia
    Korczyn, Amos D.
    Rosset, Saharon
    Friedman, Eitan
    Hassin-Baer, Sharon
    PARKINSONISM & RELATED DISORDERS, 2012, 18 (09) : 1039 - 1041
  • [28] Is carrying the G2019S mutation in the leucine-rich repeat kinase 2 gene associated with a different rate of progression of Parkinson's disease?
    Yahalom, G.
    Orlev, Y.
    Cohen, O. S.
    Inzelberg, R.
    Kozlova, E.
    Friedman, E.
    Goldbourt, U.
    Hassin-Baer, S.
    MOVEMENT DISORDERS, 2013, 28 : S316 - S316
  • [29] Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease
    Domingos, Sofia
    Duarte, Teresa
    Saraiva, Lucilia
    Guedes, Rita C.
    Moreira, Rui
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (15) : 1953 - 1977
  • [30] The NADPH Oxidase inhibitor Diapocynin Prevents Parkinson's Disease Symptoms in the Leucine-Rich Repeat Kinase 2 (LRRK2R1441G) Transgenic Mouse
    Dranka, Brian P.
    Gifford, Alison
    Ghosh, Anamitra
    Kanthasamy, Anumantha G.
    Kalyanaraman, Balaraman
    FREE RADICAL BIOLOGY AND MEDICINE, 2012, 53 : S64 - S64